Press release
Neurofibromatosis Type 2 Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - Fosun Pharmaceuticals, Spring Work Therapeutics
Neurofibromatosis Type 2 Market
Download Sample Report to know more @https://www.delveinsight.com/sample-request/neurofibromatosis-2-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Neurofibromatosis Type 2 Overview
Neurofibromatosis is a group of genetic disorders that cause tumors to form on nerve tissue. There are three types of neurofibromatosis: neurofibromatosis 1, neurofibromatosis 2 (NF2) and schwannomatosis. Neurofibromatosis Type 1 is a hereditary condition commonly associated with multiple café-au-lait spots on the skin. Beginning in early childhood, almost all people with NF1 have multiple café-au-lait spots, which are flat patches on the skin that are darker than the surrounding area. These spots increase in size and number as the individual grows older. Freckles in the underarms and groin typically develop later in childhood.
Neurofibroma is a hallmark of NF1 that is divided into the following four subtypes: cutaneous, plexiform, subcutaneous, and spinal neurofibroma. The most common forms are plexiform neurofibroma (PN) and cutaneous neurofibroma. The signs and symptoms of this condition vary widely among affected people, but they may include high blood pressure (hypertension), short stature, an unusually large head (macrocephaly), and skeletal abnormalities such as an abnormal curvature of the spine (scoliosis). Although most people with neurofibromatosis type 1 have normal intelligence, learning disabilities and attention-deficit/hyperactivity disorder (ADHD) occur frequently in affected individuals. The gene commonly associated with NF1 is also called Neurofibromatosis. Mutation or alteration in the Neurofibromatosis gene increases the risk of developing various symptoms of Neurofibromatosis, including cancerous and benign tumors. Most people with Neurofibromatosis have a mutation in the Neurofibromatosis gene. It is now believed that mutations in other genes may also produce multiple nerve tumors
Click here to learn more @https://www.delveinsight.com/report-store/neurofibromatosis-2-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Neurofibromatosis Type 2 Market Report Key Highlights
Key Companies working in the Neurofibromatosis Type 2 market include Fosun Pharmaceutical, NFlection Therapeutics, Inc., SpringWorks Therapeutics, and many others.
Key Therapies involved in Neurofibromatosis Type 2 include FCN-159, Mirdametinib, NFX-179 Gel, and many others.
Neurofibromatosis Type 2 Treatment Market
Neurofibromatosis is a common cancer predisposition genetic disease that is associated with significant morbidity and mortality.
Treatment for brain tumors that are associated with Neurofibromatosis depends on the characteristics of the tumor and the tumor location. Typically, treatment involves a combination of brain tumor surgery to resect the tumor, and radiation therapy or chemotherapy.
In 2020, Selumetinib was the first drug approved by FDA for pediatric patients aged 2 years or older with neurofibromatosis, a rare disfiguring disease. No known medical therapies are curative or preventive for patients with neurofibromatosis type 1 Neurofibromatosis. However, the development and FDA approval of selumetinib provides hope for further understanding and new drug development. Several drug trials continue to seek medications that slow or halt the growth of tumors associated with Neurofibromatosis.
Learn more about the treatment market @https://www.delveinsight.com/report-store/neurofibromatosis-2-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
The Report Covers the Neurofibromatosis Type 2 Epidemiology Segmented by:
Neurofibromatosis Type 2 incident Cases
Neurofibromatosis Type 2 treatment cases
Neurofibromatosis Type 2 prevalent cases
Neurofibromatosis Type 2 diagnosed cases
Neurofibromatosis Type 2 Drug Profile and Companies
Fosun Pharmaceuticals - FCN-159
NFlection Therapeutics - Mirdametinib
SpringWorks Therapeutics- NFX-179 Ge
And many others.
Learn more about the Key Companies and Emerging Therapies @https://www.delveinsight.com/report-store/neurofibromatosis-2-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Table of Contents
Key Insights
Neurofibromatosis Type 2 Introduction
Executive Summary of Levodopa-Induced
Dyskinesia
Disease Background and Overview
Epidemiology and patient population
Neurofibromatosis Type 2 Emerging Therapies
Neurofibromatosis Type 2 Market Outlook
Market Access and Reimbursement of Therapies
Market Drivers
Market Barriers
Appendix
Report Methodology
DelveInsight Capabilities
Disclaimer
Learn about the detailed offerings of the report @https://www.delveinsight.com/report-store/neurofibromatosis-2-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Related Reports
Neurofibromatosis Type 2 - Epidemiology Forecast
https://www.delveinsight.com/report-store/neurofibromatosis-2-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=dpr
Trending Reports By DelveInsight:
Functional Constipation Market
https://www.delveinsight.com/report-store/chronic-constipation-market
Lebers Hereditary Optic Neuropathy Lhon Market https://www.delveinsight.com/report-store/lebers-hereditary-optic-neuropathy-lhon-market
Gastric Neuroendocrine Tumors Market
https://www.delveinsight.com/report-store/gastric-neuroendocrine-tumors-market
Immune Thrombocytopenic Purpura Market
https://www.delveinsight.com/report-store/immune-thrombocytopenia-itp-market
Visceral Pain Associated With GI Disorders Market
https://www.delveinsight.com/report-store/visceral-pain-associated-with-gi-disorders-market
Bullous Pemphigoid Market
https://www.delveinsight.com/report-store/bullous-pemphigoid-market
Cyclin-dependent Kinase-like 5 Deficiency Disorder Market https://www.delveinsight.com/infographics/cyclin-dependent-kinase-like-5-cdkl5-deficiency-disorder-market
Myocarditis Market
https://www.delveinsight.com/report-store/myocarditis-market
Recurrent Blood Clots Market
https://www.delveinsight.com/report-store/recurrent-blood-clots-thrombophilia-market
Zollinger-ellison Syndrome Market
https://www.delveinsight.com/report-store/zollinger-ellison-syndrome-market
Age-related Hearing Loss Medical Device Market
https://www.delveinsight.com/blog/age-related-hearing-loss-device-market
Heart Sounds Sensors Market
https://www.delveinsight.com/report-store/heart-sounds-sensors-electronic-stethoscope-market
Hypoplastic Left Heart Syndrome Hlhs Market
https://www.delveinsight.com/report-store/hypoplastic-left-heart-syndrome-market
Infectious Arthritis/Septic Arthritis Market
https://www.delveinsight.com/report-store/infectious-arthritisseptic-arthritis-market
Plasmacytoma Market
https://www.delveinsight.com/report-store/plasmacytoma-market
Agoraphobia Market
https://www.delveinsight.com/report-store/agoraphobia-market
Clinically Isolated Syndrome CIS Market
https://www.delveinsight.com/report-store/clinically-isolated-syndrome-cis-market
Fucosidosis Market
https://www.delveinsight.com/report-store/fucosidosis-market
Major Depressive Disorder Market
https://www.delveinsight.com/report-store/major-depressive-disorder-market
Neuronal Ceroid-lipofuscinoses Market
https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market
Orthotic Devices Market
https://www.delveinsight.com/report-store/orthotic-devices-market
DelveInsight Business Research LLP
Adya Kaul
info@delveinsight.com
https://www.delveinsight.com
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neurofibromatosis Type 2 Market is Expected to Show a Healthy Growth Rate During the Study Period (2019-2032)| Key Companies - Fosun Pharmaceuticals, Spring Work Therapeutics here
News-ID: 3152604 • Views: …
More Releases from DelveInsight Business Research LLP
RNA Interference Pipeline Drugs Insights Report 2025: Clinical Trial Studies, EM …
DelveInsight's "RNA Interference Pipeline Insight 2025" report provides comprehensive insights about 20+ companies and 90+ pipeline drugs in the RNA Interference pipeline landscape. It covers the RNA Interference pipeline drug profiles, including clinical and nonclinical stage products. It also covers the RNA Interference therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
Amyotrophic Lateral Sclerosis Pipeline Drugs Insights Report 2025: Clinical Tria …
DelveInsight's, "Amyotrophic Lateral Sclerosis Pipeline Insight 2025" report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in Amyotrophic Lateral Sclerosis pipeline landscape. It covers the Amyotrophic Lateral Sclerosis pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Amyotrophic…
NK Cell Therapy Pipeline Outlook Report 2025: Clinical Trial Studies, EMA, PDMA, …
DelveInsight's, "NK Cell Therapies Pipeline Insight, 2025" report provides comprehensive insights about 140+ companies and 160+ pipeline drugs in NK Cell Therapies pipeline landscape. It covers the NK Cell Therapies pipeline drug profiles, including clinical and nonclinical stage products. It also covers the NK Cell Therapies pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the…
TCR Therapy Pipeline Drugs Insights Report 2025: Clinical Trials, EMA, PDMA, FDA …
DelveInsight's "TCR Therapy Pipeline Insight 2025" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the TCR Therapy pipeline landscape. It covers the TCR Therapy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the TCR Therapy therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Discover the latest drugs and treatment…
More Releases for Neurofibroma
Neurofibroma Market to Reach USD 1.1 Billion by 2034
The global Neurofibroma Market is experiencing steady momentum, driven by increasing prevalence of neurofibromatosis, advancements in molecular diagnostics, and rising research funding for rare genetic disorders. As a benign nerve sheath tumor with potential to transform into malignant forms in some cases, neurofibroma represents a unique therapeutic challenge. The industry is evolving through new treatment modalities, robust diagnostic frameworks, and targeted therapies that are expanding patient access worldwide.
Download Full PDF…
Plexiform Neurofibroma Market Set to Grow According to Forecasts 2016 - 2024
One of the most commonly occurring single gene disorder affecting nervous system, neurofibromatosis type I or NF1 involves a number of skin abnormalities. Patients with NF1 have several tumors associated with nervous system and other body organs. These tumors are non-cancerous, known as neurofibromas, and are often formed on or under the skin, and even along the nerves throughout the body.
Read Report Overview - https://www.transparencymarketresearch.com/plexiform-neurofibroma-market.html
The most commonly observed tumor is…
Plexiform Neurofibroma Market: Expected Advancements & Global Industry Analysis …
One of the most commonly occurring single gene disorder affecting nervous system, neurofibromatosis type I or NF1 involves a number of skin abnormalities. Patients with NF1 have several tumors associated with nervous system and other body organs. These tumors are non-cancerous, known as neurofibromas, and are often formed on or under the skin, and even along the nerves throughout the body.
The most commonly observed tumor is cutaneous neurofibroma, plexiform neurofibroma…
Plexiform Neurofibroma Market Trends and Growth Propellers 2024
One of the most commonly occurring single gene disorder affecting nervous system, neurofibromatosis type I or NF1 involves a number of skin abnormalities. Patients with NF1 have several tumors associated with nervous system and other body organs. These tumors are non-cancerous, known as neurofibromas, and are often formed on or under the skin, and even along the nerves throughout the body.
Browse through Plexiform Neurofibroma Market report to know what factors…
Plexiform Neurofibroma Market: Emerging Trends and New Technologies Research 201 …
One of the most commonly occurring single gene disorder affecting nervous system, neurofibromatosis type I or NF1 involves a number of skin abnormalities. Patients with NF1 have several tumors associated with nervous system and other body organs. These tumors are non-cancerous, known as neurofibromas, and are often formed on or under the skin, and even along the nerves throughout the body.
The most commonly observed tumor is cutaneous neurofibroma, plexiform neurofibroma…
Plexiform Neurofibroma Market: Evolving Technology, Trends and Industry Analysis …
One of the most commonly occurring single gene disorder affecting nervous system, neurofibromatosis type I or NF1 involves a number of skin abnormalities. Patients with NF1 have several tumors associated with nervous system and other body organs. These tumors are non-cancerous, known as neurofibromas, and are often formed on or under the skin, and even along the nerves throughout the body.
The most commonly observed tumor is cutaneous neurofibroma, plexiform neurofibroma…
